Welcome to our dedicated page for Nanobiotix news (Ticker: NBTX), a resource for investors and traders seeking the latest updates and insights on Nanobiotix stock.
Nanobiotix S.A. develops nanotechnology-based therapeutic platforms for cancer and other major diseases as a late-stage clinical biotechnology company. Its news commonly centers on JNJ-1900 (NBTXR3), a hafnium oxide nanoparticle radioenhancer administered by intratumoral injection and activated by radiotherapy, including head and neck cancer and lung cancer development updates, clinical data presentations, and regulatory communications.
Company updates also cover the Nanoprimer platform for bioavailability and biodistribution, preclinical work with lipid nanoparticle-delivered therapies, collaborations with Johnson & Johnson, Janssen and MD Anderson, periodic operating and financial results, and recurring disclosures of share capital and voting rights for its Euronext Paris and Nasdaq-listed securities.
Nanobiotix (NASDAQ: NBTX) has appointed Bart Van Rhijn as the new CFO, succeeding Philippe Mauberna, who served for eight years. Van Rhijn comes with a strong background in financial management and business development, particularly in the pharmaceutical sector. His leadership is expected to facilitate the launch of the company’s second clinical registration study for NBTXR3 in head and neck cancer and to support expansion in immunotherapy and other solid tumor therapies. Mauberna will remain temporarily to assist during this transition.
NANOBIOTIX (NASDAQ: NBTX), a late-stage biotechnology company, announced that CEO Laurent Levy will present the company's latest developments at the Jefferies Virtual Healthcare Conference on June 4 at 8:00 AM ET (14:00 CET). The event will be available via a live webcast and an archived recording on the company’s website. Nanobiotix focuses on innovative physics-based treatments for cancer and is known for its lead candidate NBTXR3, which has received market authorization in Europe for treating soft tissue sarcoma under the brand name Hensify®.
Nanobiotix (NASDAQ: NBTX) announced the appointment of Dr. Gary Phillips as the new chairman of its supervisory board, succeeding Laurent Condomine. Dr. Phillips brings extensive experience from his roles at OrphoMed and Mallinckrodt Pharmaceuticals. His appointment coincides with the company's strategic focus on advancing its development programs, particularly in head and neck cancer and immunotherapy. Condomine, who led the board for 11 years, oversaw significant milestones, including the launch of NBTXR3, which has received European market authorization. This leadership transition is expected to enhance Nanobiotix's growth trajectory.
Summary not available.
Nanobiotix (NASDAQ: NBTX) announced updates at the 2021 ASCO Annual Meeting regarding its leading oncology product NBTXR3 for treating head and neck cancer and advanced cancers. The data shows NBTXR3's potential to enhance the effectiveness of radiotherapy and immunotherapy. In a phase I study, patients with locally advanced head and neck squamous cell carcinoma exhibited an 82.5% objective response rate. The company is set to launch a pivotal phase III trial for NBTXR3 in 2021. Positive long-term safety data from a soft tissue sarcoma study was also reported.
NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX) announced that CEO Laurent Levy will present at the UBS Global Healthcare Virtual Conference on May 24, 2021, at 7:00 AM ET. A live webcast will be available on their website, with a replay to follow. The company, founded in 2003 and headquartered in Paris, focuses on physics-based approaches to cancer treatment. Its lead product, NBTXR3, is authorized in Europe for soft tissue sarcoma under the brand Hensify®.
Nanobiotix (NASDAQ: NBTX) announces a partnership with LianBio to develop NBTXR3, a new cancer treatment, in Greater China and other Asian markets. LianBio will handle commercial development, with Nanobiotix receiving a $20 million upfront payment and potential milestone payments totaling up to $220 million. The collaboration includes participation in a Phase III study for head and neck cancer. NBTXR3 has shown promise in treating solid tumors and has received Fast Track designation from the FDA for certain patient groups.
Nanobiotix (NASDAQ: NBTX) announces a partnership with LianBio to develop NBTXR3, an innovative radioenhancer for cancer treatment, in Greater China and other Asian markets. Nanobiotix will receive a $20 million upfront payment and potential milestone payments of up to $220 million. The agreement allows LianBio to obtain exclusive commercialization rights for NBTXR3, while Nanobiotix continues to fund its global phase III study for head and neck cancer. This strategic collaboration aims to enhance treatment options for cancer patients in the region.
Nanobiotix (NASDAQ: NBTX) reported operational progress and cash position for Q1 2021. The company has €107.1 million in cash, significantly up from €28 million in Q1 2020. Despite this, no revenue was generated in Q1 2021, a drop from €24,000 in Q1 2020 due to the end of a collaboration with PharmaEngine. Notable advancements include promising preclinical data for NBTXR3 and the initiation of a phase I trial in esophageal cancer. Collaborations with Sanofi and the retention of IP rights in the Asia-Pacific region were also highlighted.
NANOBIOTIX (NASDAQ: NBTX) announced it will present new data from its oncology pipeline at the 2021 ASCO Annual Meeting from June 4-8. Four abstracts will showcase NBTXR3, a potential first-in-class radioenhancer, across various tumor types and in combination with anti-PD-1 therapies. Key studies include an updated analysis of NBTXR3 in head and neck cancer, with plans for a global phase III trial in 2021. The company will host a virtual investor event on June 11 to discuss these results.